Skip to main content

Most Men Choose Active Surveillance for Low-Risk Prostate Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 22, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Jan. 22, 2024 -- More than half of newly diagnosed patients with low-risk prostate cancer (LRPC) chose active surveillance (AS), with recommendation from a urologist being the strongest determinant of AS uptake, according to a study published online Jan. 22 in Cancer.

Jinping Xu, M.D., from the Wayne State University School of Medicine in Detroit, and colleagues examined factors influencing AS uptake in a survey administered to Black and White newly diagnosed patients with LRPC who were aged 75 years or older. Data were included for 1,688 participants identified through metro‐Detroit and Georgia population‐based cancer registries.

The researchers found that 57 percent of the study participants chose AS over definitive treatment (51 and 61 percent of Black and White participants, respectively). Older age, White race, and higher education were patient factors associated with initial AS uptake in an unadjusted analysis. None of these factors were significant predictors of AS uptake after adjustment for covariates. AS recommendation by a urologist was the strongest determinant of AS uptake (adjusted prevalence ratio, 6.59). Shared patient-physician treatment decision, greater prostate cancer knowledge, and residence in metro‐Detroit compared with Georgia were other factors associated with the decision to undergo AS. The likelihood of choosing AS was lower for men whose decision was strongly influenced by the desire to achieve "cure" or "live longer" with treatment and those who perceived their LRPC diagnosis as more serious.

"This indicates that patient perceptions and acceptance of AS have improved over time, although geographical and racial differences in uptake remain," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.